Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Momelotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Cyt387, 1056634-68-4, Cyt-387, Cyt 387, N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide, Cyt 11387
    Molecular Formula
    C23H22N6O2
    Molecular Weight
    414.5  g/mol
    InChI Key
    ZVHNDZWQTBEVRY-UHFFFAOYSA-N
    FDA UNII
    6O01GMS00P
    Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
    2.1.2 InChI
    InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
    2.1.3 InChI Key
    ZVHNDZWQTBEVRY-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N
    2.2 Other Identifiers
    2.2.1 UNII
    6O01GMS00P
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Cyt 387

    2. Cyt-387

    3. Cyt387

    4. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

    2.3.2 Depositor-Supplied Synonyms

    1. Cyt387

    2. 1056634-68-4

    3. Cyt-387

    4. Cyt 387

    5. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide

    6. Cyt 11387

    7. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

    8. Gs-0387

    9. Momelotinib (cyt387)

    10. Cyt-11387

    11. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide

    12. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

    13. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

    14. 6o01gms00p

    15. Chembl1078178

    16. Cyt-0387

    17. Cyt11387

    18. Mfcd16038899

    19. Lm-1149

    20. N-(cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide

    21. N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide

    22. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-

    23. Momelotinib [usan]

    24. Momelotinib [usan:inn]

    25. Momelotinibum

    26. Unii-6o01gms00p

    27. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-

    28. C87

    29. Momelotinib [inn]

    30. Momelotinib (usan/inn)

    31. Momelotinib [who-dd]

    32. Mls006011154

    33. Gtpl7791

    34. Schembl2237234

    35. Chebi:91407

    36. Ex-a260

    37. Dtxsid801026049

    38. Hms3244k19

    39. Hms3244k20

    40. Hms3244l19

    41. Hms3295i01

    42. Hms3655d12

    43. Hms3744c15

    44. Bcp02328

    45. Cyt387, Cyt11387

    46. Cyt387,cyt 11387

    47. Momelotinib (cyt387,cyt-387)

    48. Bdbm50311017

    49. Nsc767598

    50. Nsc800800

    51. S2219

    52. Zinc43199890

    53. Akos015904624

    54. N-(cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide

    55. Bcp9000570

    56. Ccg-264946

    57. Cs-0053

    58. Db11763

    59. Nsc-767598

    60. Nsc-800800

    61. Sb14602

    62. Ncgc00244257-01

    63. Ncgc00244257-08

    64. Ac-23162

    65. As-19389

    66. Hy-10961

    67. Smr004702928

    68. Sy060668

    69. Ft-0755949

    70. Sw219679-1

    71. D10315

    72. A857769

    73. Q252602

    74. J-001468

    75. J-523159

    76. Brd-k87737963-001-01-1

    77. N-(cyanomethyl)-4-(2-(4-morpholinoanilino)pyrimidin-4-yl)benzamide

    78. N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide

    79. N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide

    80. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide

    81. Benzamide,n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-

    82. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide;cyt387

    83. Cyt 11387, Cyt-387, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

    2.4 Create Date
    2008-12-01
    3 Chemical and Physical Properties
    Molecular Weight 414.5 g/mol
    Molecular Formula C23H22N6O2
    XLogP32.6
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count6
    Exact Mass414.18042397 g/mol
    Monoisotopic Mass414.18042397 g/mol
    Topological Polar Surface Area103 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity615
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of myelofibrosis

    Treatment of post-polycythaemia vera myelofibrosis, Treatment of polycythaemia vera, Treatment of post-essential thrombocythaemia myelofibrosis, Treatment of essential thrombocythaemia, Treatment of acute lymphoblastic leukaemia

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)